Ultomiris
FDA approves AstraZeneca’s Ultomiris for NMOSD treatment
March 25, 2024Medical Communications AstraZeneca, FDA, Neurology, Ultomiris, neuromyelitis optica spectrum disorder
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab-cwvs) as the first and only …
AstraZeneca’s Ultomiris approved in Japan for prevention of relapses in patients with NMOSD
May 30, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris
AstraZeneca has announced that Ultomiris (ravulizumab) has been approved in Japan as a long-acting C5 complement inhibitor for the prevention …
AstraZeneca’s Ultomiris approved in EU for adults firm NMOSD
May 11, 2023Medical Communications AstraZeneca, NMOSD, Neurology, Ultomiris, neurology
AstraZeneca has announced the approval of Ultomiris (ravulizumab) in the European Union (EU) for the treatment of adult patients with …
FDA approves Alexion’s Ultomiris in atypical haemolytic uremic syndrome for adults and children
October 21, 2019Sales and Marketing Alexion, FDA, Ultomiris, pharma, rare disease
The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …
European approval for Alexion’s Ultomiris in rare blood disease
July 4, 2019Sales and Marketing Alexion, Europe, Ultomiris, paroxysmal nocturnal haemoglobinuria
Alexion has received marketing authorisation from the European Commission for its long-acting C5 complement inhibitor Ultomiris (ravulizumab) in the treatment …
Latest content
